Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV
Status:
Not yet recruiting
Trial end date:
2023-02-23
Target enrollment:
Participant gender:
Summary
This is a phase2, randomized, single-blind, placebo controlled and multi-center study in
adults with chronic hepatitis B virus. The study is aimed at evaluating efficacy and safety
of ASC42 in combination with entecavir and pegylated interferon α-2a in subjects with chronic
hepatitis B virus.